The medicine is utilized for addressing specific movement disorders and providing support against certain viral illnesses.

The medication is applied across domains where additional symptomatic support is needed, addressing symptoms of increased neurological or muscular activity and symptoms related to systemic imbalance. It is commonly used to help with symptoms in Parkinson's disease, including stiffness and slowness of movement, and to ease involuntary movements (dyskinesia) arising from other chronic treatments. It is also relevant for managing drug-induced motor symptoms like restlessness and muscle tension. Furthermore, it is applicable within clinical settings that involve acute or disruptive symptom patterns caused by the Influenza A virus, where it supports both prevention and the reduction of acute viral symptoms.

“This medication contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.”

Quick Fact: Relief for Involuntary Movements

Context	Symptom Managed	Patient Benefit
Chronic Neurological Care	Disruptive Dyskinesia	Supports the patient in coping more steadily with movement fluctuations
Antipsychotic Treatment Support	Restlessness (Akathisia)	Provides supportive relief when symptoms interfere with routine activities
Seasonal Health Support	Acute Viral Symptoms (Fever, Malaise)	Contributes to easing the overall symptom load during illness

Regulatory References

1. NIH MedlinePlus overview

The eligibility for using Simon (Amantadine Hydrochloride) is strictly defined by regulatory authorities based on population characteristics and underlying health status.

Contraindicated Populations

Simon is contraindicated in patients with a known hypersensitivity to the drug or its components. Absolute non-eligibility is established for those with End-Stage Renal Disease (ESRD), a history of epilepsy or convulsions, or a history of gastric ulceration. Furthermore, the medication is contraindicated for women who are pregnant or planning to become pregnant, and for patients with untreated angle-closure glaucoma.

Restricted and Not-Established Use

The drug is generally not recommended for women who are breastfeeding. Safety and efficacy have not been established for infants younger than one year of age, or for the extended-release formulations in children under 18. Patients with any degree of renal impairment less severe than ESRD must have their dosage restricted and adjusted based on clearance. Caution is required when prescribing to older adults due to their potential for reduced renal clearance, and to individuals with Congestive Heart Failure or a history of severe psychiatric disorders.

Interaction Map: Interactions with other medicines and products — Official Regulatory Information for Amantadine (Simon)

---

Interaction Scope

Property	Description
Medicinal product categories with documented interactions	Anticholinergic Agents, Diuretics (specifically Triamterene-containing combinations), Drugs Affecting Urinary pH (Alkalinizing and Acidifying Agents), CNS Stimulants, Levodopa, Neuroleptics, Live Attenuated Influenza Vaccine.
Specific interacting medicines (if explicitly listed)	Triamterene, Hydrochlorothiazide, Trimethoprim, Acetazolamide, Live Attenuated Influenza Vaccine (LAIV), Levodopa.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic: Reduced renal clearance leading to higher plasma levels (e.g., with Triamterene/Hydrochlorothiazide). Altered urinary pH modifying excretion rate. Pharmacodynamic: Additive Central Nervous System (CNS) effects.
Timing-based interaction rules (if applicable)	Amantadine use must be avoided for two weeks prior to administration of the Live Attenuated Influenza Vaccine (LAIV) and for 48 hours following LAIV administration, to prevent interference with vaccine efficacy.
Population-specific interaction notes (if applicable)	The extended-release product is formally contraindicated in patients with End-Stage Renal Disease (Creatinine Clearance <15 mL/min), a constraint due to the risk of accumulation and toxicity from severely decreased clearance.
Interaction-related restrictions	Co-administration with Alcohol (Ethanol) is not recommended due to the increased potential for additive CNS-related effects and the risk of rapid drug release (dose-dumping) from extended-release formulations. Co-use with Triamterene/Hydrochlorothiazide is generally not recommended.

---

Resulting Interaction Structure

Official interaction statements:

• The use of combination diuretics containing Triamterene may substantially increase drug plasma levels due to reduced renal clearance, necessitating regulatory caution.
• Co-administration with Anticholinergic Agents, Levodopa, or other CNS-active substances may result in additive pharmacodynamic effects, such as increased CNS-related or atropine-like effects.
• The drug’s excretion rate is sensitive to urinary pH, where acidification can increase clearance and alkalinization can decrease it.

Connection to the overall interaction profile (2–4 sentences):

Government prescribing information defines the product's interaction profile largely by its pharmacokinetic sensitivity to renal drug clearance mechanisms, which governs restrictions involving diuretics and cautions in renal impairment. Secondly, the profile identifies additive pharmacodynamic risks with co-administered CNS agents, requiring regulatory prudence. Formal timing constraints are explicitly imposed for use relative to the Live Attenuated Influenza Vaccine, as documented by US and European health authorities.

The molecule's mechanism of action involves two distinct pharmacological domains. In the central nervous system, it promotes the release of endogenous dopamine from nerve terminals and functions as a weak, non-competitive antagonist of the excitatory N-methyl-D-aspartate (NMDA) receptor. This dual action enhances dopaminergic signaling while reducing excessive glutamatergic activity, which contributes to the functional rebalancing of extrapyramidal motor pathway activity.

Separately, the molecule targets the Influenza A virus by physically obstructing the M2 protein, a proton-selective ion channel on the viral envelope. Blocking this channel inhibits the necessary acidification of the viral core, which results in the suppression of the crucial uncoating process and subsequent inhibition of viral genetic material release into the host cell.

This M2 mechanism is structurally constrained, resulting in functional non-interaction with the M2-like protein of Influenza B virus and susceptibility to a loss of blockade capacity due to M2 protein mutations.

Administration Overview

Simon is an oral medication that should be taken according to the schedule provided by a healthcare professional. Consistency in the timing of doses is an important factor in maintaining steady levels of the medication in the body.

General Guidance

• Method of Intake: The medication is typically swallowed whole. It can be taken with or without food, though individual tolerance may vary. If gastrointestinal upset occurs, taking the dose with a light meal may be helpful.
• Consistency: Taking the medication at the same time each day helps establish a routine and ensures the drug's efficacy is monitored accurately over time.
• Hydration: It is recommended to take the medication with a full glass of water.

Handling and Storage

Proper handling of the medication ensures its integrity remains intact until the point of consumption:

• Storage Environment: Keep the medication in its original packaging to protect it from environmental factors such as light and moisture.
• Temperature: Store at room temperature, away from excessive heat or freezing conditions. Avoid storing the medication in areas with high humidity, such as bathroom cabinets.
• Missed Doses: If a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be bypassed to maintain the regular schedule. Do not double the intake to compensate for a missed dose.

Important Considerations

Before beginning use, patients should ensure they have discussed their full medical history and any concurrent medications with a provider to identify potential interactions. Monitoring by a healthcare professional is standard practice to evaluate how the body responds to the medication.

Research evidence / Overview of studies for Simon

Research evidence for Simon explores its role across several clinical areas, focusing on movement disorders and historical use against a specific viral infection.

For Levodopa-Induced Dyskinesia (LID) in Parkinson's disease, evidence is derived primarily from randomized controlled trials (RCTs). These studies examined changes in dyskinesia severity scores and the duration of time patients spent in observed motor states. Findings describe patterns related to changes in severity measured during short-term follow-up. However, the durability of these observed patterns beyond the initial study period is an area where evidence is still emerging, and long-term effects are not fully established.

Research for core motor symptoms in Parkinson's disease, such as rigidity and slowness, is based largely on older and historical trials. These studies reported small measured changes in outcomes related to physical discomfort. The evidence quality varies across these older studies, and the current research landscape has been affected by the introduction of newer drug classes.

Simon was also observed in RCTs for influencing functional recovery following severe traumatic brain injury (TBI). These trials monitored functional status and levels of consciousness. While some studies described patterns related to the timing of functional milestones, findings were mixed, and follow-up durations were short, limiting certainty regarding sustained recovery.

For Influenza A virus infection, the evidence base is primarily historical, derived from older trials that studied prevention and symptom duration. Current certainty remains low for this indication, as public health surveillance reports data showing widespread viral resistance to this compound. Across all indications, evidence for certain subgroups, such as children and pregnant individuals, remains insufficient, and follow-up durations were generally limited.

Common questions about Simon (FAQ)

---

Q: What is Simon most commonly prescribed for?

Official regulatory documents indicate that this medicine is approved for two primary uses: the prophylaxis and treatment of Influenza A virus infection, and the management of symptoms associated with Parkinson’s disease (including certain drug-induced movement problems).

---

Q: How quickly does Simon start to work after taking it?

Official information regarding the use of the medicine for Parkinson’s symptoms suggests an effect may begin to be observed within about 48 hours following the start of immediate-release dosing. Observing the full effects of treatment may take up to two weeks.

---

Q: What happens if you suddenly stop taking Simon?

Regulatory labeling includes a specific caution against abruptly stopping this medicine, especially in patients managing Parkinson's disease. Sudden cessation has been associated with serious complications, including a Parkinsonian crisis or a syndrome resembling Neuroleptic Malignant Syndrome (NMS).

---

Q: What is the typical timeframe before knowing if Simon is working?

The timeframe for observing improvement in Parkinson’s symptoms is sometimes noted within two days, based on clinical observations. However, official information suggests that it can take up to two weeks for the full effects of the medicine to be observed.

---

Q: Is Simon available as a generic medicine?

According to official regulatory and pharmaceutical availability records, the medicine is available in both brand-name and generic formulations.

---

Q: What is the main classification of the drug Simon?

Official classification documents list the medicine as both an Antiparkinson Agent and an Antiviral. Its pharmacological activity is described as affecting the M2 protein of the Influenza A virus and relating to the dopamine system.

---

Q: How is Simon eliminated from the body?

Official pharmacological documents state that the medicine is primarily eliminated from the body through the urine, mostly as the unchanged drug. Its clearance relies primarily on the kidneys.

---

Q: Can Simon cause weight gain or loss?

Regulatory documents listing the adverse reactions associated with the medicine include loss of appetite (anorexia) as a reported side effect. This potential effect is noted in the official prescribing information.

---

Q: Is it normal to feel tired when first starting Simon?

Yes, regulatory documents indicate that drowsiness and unusual tiredness or weakness are side effects that have been reported by patients using this medicine. This is noted as a possible effect in the official prescribing information.

---

Q: How long can a person safely stay on Simon?

Official regulatory documents do not specify a maximum duration for treatment. For people using the medicine long-term, the prescribing information emphasizes the necessity of periodic monitoring by a healthcare provider and a regular evaluation of the treatment’s effectiveness.

---

Q: What are the most common side effects of Simon?

Commonly observed side effects, as reported in regulatory documents, include dry mouth, nausea, constipation, dizziness, insomnia, and hallucinations. A complete list of side effects is available in the official prescribing information.

---

Q: Can people with high blood pressure use Simon?

Official information states that a history of cardiac conditions, including low blood pressure (hypotension) or congestive heart failure, should be communicated to the healthcare provider before beginning use, as outlined in regulatory information.

---

Q: Does Simon affect fertility or pregnancy planning?

Based on animal studies, the medicine may cause fetal harm and has been reported to impair fertility in both male and female rats. Regulatory documents indicate that women of child-bearing potential may be advised to use effective contraception during and shortly after treatment.

---

Q: What are the reported major/serious side effects of Simon?

Serious side effects reported in official documents include a syndrome resembling Neuroleptic Malignant Syndrome (NMS). Other serious effects include psychotic behavior, hallucinations, and the risk of developing or worsening suicidal ideation or behavior. Official information states that severe emotional or mood changes can occur.

---

Q: Who is excluded from being able to use Simon?

The medicine is formally contraindicated in patients with a known hypersensitivity (severe allergic reaction) to the drug or any of its components. The extended-release formulation is also contraindicated in those with End-Stage Renal Disease, due to significantly impaired kidney function.

---

Q: Does Simon cause any known emotional or mood changes?

Official documents list potential psychiatric side effects, including feelings of depression, anxiety, confusion, and a risk of developing or worsening suicidal thoughts and impulse control behaviors. Individuals should be aware of these potential effects.

---

Q: What does official guidance say about Simon and driving?

Because the medicine can cause side effects such as dizziness, blurred vision, or unexpectedly falling asleep (somnolence), official regulatory guidance specifies that driving or operating heavy machinery should be avoided. These activities should be avoided until the individual is aware of how the medicine affects their alertness.

---

Q: Are children allowed to use Simon?

Regulatory labeling describes specific dosing regimens for the use of this medicine in children. Its use in the pediatric population is primarily for the prophylaxis and treatment of Influenza A. Pediatric use is based on the determination of a healthcare provider.

---

Q: What if I have an allergic reaction to Simon?

Official regulatory documents specify that the medicine is contraindicated for anyone who has a known hypersensitivity (allergic reaction) to the drug or any of its components. The contraindication is based on a known hypersensitivity.

---

Q: What are the study results regarding Simon's effectiveness?

Clinical research evidence in official documents has examined the drug’s effectiveness in reducing symptoms associated with Parkinson’s disease and in the prophylaxis and treatment of Influenza A.

---

Q: Does Simon make other medicines less effective?

Regulatory guidance highlights an interaction concern with the Live Attenuated Influenza Vaccine (LAIV). Official instructions state that the use of this medicine must be avoided for two weeks prior to and 48 hours following LAIV to prevent potential interference with the vaccine’s efficacy.

---

Q: Why is Simon not available over the counter?

The medicine is classified by regulatory authorities as a prescription-only drug. This status means a licensed healthcare provider must issue a prescription before the medicine can be obtained for use.

---

Q: What are the conditions for stopping Simon?

The decision to discontinue the medicine is made in consultation with a healthcare provider. Official warnings caution that stopping the drug abruptly may lead to serious side effects. Official warnings note that a gradual reduction in dose is typically employed to manage the risk of serious side effects.

---

Q: Can Simon affect the results of lab tests?

Official regulatory labeling recommends that during treatment, certain parameters, such as renal function and blood electrolytes, should be monitored. This monitoring is especially relevant in cases of compromised kidney function.

---

Q: Can Simon affect sleep patterns?

Yes, official reports indicate the medicine can cause effects that disturb sleep patterns. These side effects include insomnia (difficulty sleeping) and abnormal dreams. Some patients have also reported experiencing falling asleep during daily activities.

---

Q: Are there different strengths or forms of Simon available?

The drug is available in several formulations as described in official documents, including oral capsules, tablets, and an oral solution (syrup). These come in various strengths, depending on the specific product type prescribed.

---

Q: Does Simon require regular blood tests or monitoring?

Official guidance indicates that for patients with compromised renal function, regular monitoring of plasma concentrations and dosage adjustment based on the patient's creatinine clearance is often suggested. The need for monitoring beyond these parameters is determined by the healthcare provider.

---

Q: Is Simon a controlled substance?

The medicine is classified as a prescription-only drug. Its regulatory classification status is determined by the specific governing body and may vary by region.

---

Q: Why does Simon have a warning about [specific organ/system] in the documentation?

Regulatory documents include warnings concerning serious potential side effects related to the Central Nervous System (CNS), such as hallucinations and suicidal ideation. There are also warnings related to use in patients with severe renal impairment.

---

Q: Can I take Simon if I have a history of liver issues?

Official documents indicate the medicine has minimal hepatic metabolism. Official information indicates that a history of liver disease is a condition that must be reported to the healthcare provider prior to use.

How to Store and Dispose of Simon?

The storage and disposal of this medication, which contains Amantadine Hydrochloride, must strictly follow official regulatory requirements to ensure product quality and safety.

Required Storage Conditions

Condition	Requirement
Temperature	Store at controlled room temperature, specifically 25 C (77 F), with excursions permitted up to 30 C.
Protection	Protect the medicine from freezing and moisture.
Packaging	Keep the product in the original container and ensure the container is tightly closed.
Child Safety	Store the product out of the sight and reach of children.

Official Disposal Instructions

Unused or expired product must be disposed of according to local requirements for pharmaceutical waste. Regulatory labeling specifies that the medicine must not be disposed of via wastewater or routine household waste to comply with environmental protection guidelines.